Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;6(8):914-925.
doi: 10.1530/EC-17-0237. Epub 2017 Oct 26.

AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation

Affiliations

AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation

Paula Bruna Araujo et al. Endocr Connect. 2017 Nov.

Abstract

Aryl hydrocarbon receptor-interacting protein (AIP) gene mutations (AIPmut) are the most frequent germline mutations found in apparently sporadic pituitary adenomas (SPA). Our aim was to evaluate the frequency of AIPmut among young Brazilian patients with SPA. We performed an observational cohort study between 2013 and 2016 in a single referral center. AIPmut screening was carried out in 132 SPA patients with macroadenomas diagnosed up to 40 years or in adenomas of any size diagnosed until 18 years of age. Twelve tumor samples were also analyzed. Leukocyte DNA and tumor tissue DNA were sequenced for the entire AIP-coding region for evaluation of mutations. Eleven (8.3%) of the 132 patients had AIPmut, comprising 9/74 (12%) somatotropinomas, 1/38 (2.6%) prolactinoma, 1/10 (10%) corticotropinoma and no non-functioning adenomas. In pediatric patients (≤18 years), AIPmut frequency was 13.3% (2/15). Out of the 5 patients with gigantism, two had AIPmut, both truncating mutations. The Y268* mutation was described in Brazilian patients and the K273Rfs*30 mutation is a novel mutation in our patient. No somatic AIP mutations were found in the 12 tumor samples. A tumor sample from an acromegaly patient harboring the A299V AIPmut showed loss of heterozygosity. In conclusion, AIPmut frequency in SPA Brazilian patients is similar to other populations. Our study identified two mutations exclusively found in Brazilians and also shows, for the first time, loss of heterozygosity in tumor DNA from an acromegaly patient harboring the A299V AIPmut Our findings corroborate previous observations that AIPmut screening should be performed in young patients with SPA.

Keywords: AIP; germline mutations; sporadic pituitary adenomas; tumor suppressor gene.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pedigrees of the families of the probands. The scheme shows the three family trees (A, B and C) of the probands (black squares with an arrow). Male family members are represented by squares, females by circles.
Figure 2
Figure 2
Sparsely granulated somatotropinoma from the patient with the AIPmut c.*14C > A. Pituitary adenoma stained with Hematoxilin & Eosin, consisting of eosinophilic cells (A and B) and immunopositive for GH (C), which are sparsely granulated (dot staining) with CAM 5.2 (D). There are blood cells and cholesterol clefts among the epithelial cells (A).
Figure 3
Figure 3
Sequencing electropherograms showing AIPmut c.896C > T (A299V) in exon 6. Black arrows show the position of the nucleotide change. (A) Blood leukocyte genomic DNA from acromegaly patient. (B) Tumor genomic DNA from acromegaly patient with loss of heterozygosity (LOH).

Similar articles

  • High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas.
    Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, Elenkova A, Tabarin A, Desailloud R, Maiter D, Schürmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Montañana CF, Hana V, Halaby G, Delemer B, Aizpún JI, Sonnet E, Longás AF, Hagelstein MT, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A. Tichomirowa MA, et al. Eur J Endocrinol. 2011 Oct;165(4):509-15. doi: 10.1530/EJE-11-0304. Epub 2011 Jul 13. Eur J Endocrinol. 2011. PMID: 21753072
  • Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study.
    Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montañana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabaté MI, Villa C, Popelier M, Salvatori R, Jennings J, Longás AF, Labarta Aizpún JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A. Daly AF, et al. J Clin Endocrinol Metab. 2010 Nov;95(11):E373-83. doi: 10.1210/jc.2009-2556. Epub 2010 Aug 4. J Clin Endocrinol Metab. 2010. PMID: 20685857
  • Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers.
    Hernández-Ramírez LC, Gabrovska P, Dénes J, Stals K, Trivellin G, Tilley D, Ferrau F, Evanson J, Ellard S, Grossman AB, Roncaroli F, Gadelha MR, Korbonits M; International FIPA Consortium. Hernández-Ramírez LC, et al. J Clin Endocrinol Metab. 2015 Sep;100(9):E1242-54. doi: 10.1210/jc.2015-1869. J Clin Endocrinol Metab. 2015. PMID: 26186299 Free PMC article.
  • AIP mutations and gigantism.
    Rostomyan L, Potorac I, Beckers P, Daly AF, Beckers A. Rostomyan L, et al. Ann Endocrinol (Paris). 2017 Jun;78(2):123-130. doi: 10.1016/j.ando.2017.04.012. Epub 2017 May 5. Ann Endocrinol (Paris). 2017. PMID: 28483363 Review.
  • Mutations of the gene for the aryl hydrocarbon receptor-interacting protein in pituitary adenomas.
    Cazabat L, Guillaud-Bataille M, Bertherat J, Raffin-Sanson ML. Cazabat L, et al. Horm Res. 2009;71(3):132-41. doi: 10.1159/000197869. Epub 2009 Feb 3. Horm Res. 2009. PMID: 19188737 Review.

Cited by

References

    1. Gadelha MR, Trivellin G, Hernández Ramírez LC, Korbonits M. Genetics of pituitary adenomas. Frontiers of Hormone Research 2013. 41 111–140. - PubMed
    1. Melmed S. Pathogenesis of pituitary tumors. Nature Reviews Endocrinology 2011. 7 257–266. ( 10.1038/nrendo.2011.40) - DOI - PubMed
    1. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006. 312 1228–1230. ( 10.1126/science.1126100) - DOI - PubMed
    1. Trivellin G, Korbonits M. AIP and its interacting partners. Journal of Endocrinology 2011. 210 137–155. ( 10.1530/JOE-11-0054) - DOI - PubMed
    1. Swedenborg E, Pongratz I. AhR and ARNT modulate ER signaling. Toxicology 2010. 268 132–138. ( 10.1016/j.tox.2009.09.007) - DOI - PubMed

LinkOut - more resources